Lineage Cell Therapeutics, Inc.

LCTX

Exchange: NYSE
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0000876343

SEC filings (opens in a new tab)

No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023 All holders in Q3 2023

13F holders of LCTX: Q3 2023 compared with Q4 2023
Measure	Q3 2023	Q4 2023	Change
Holders	104	115	+11
Shares	75.5M	75.7M	+202.5K (+0.3%)
Value	$89.1M	$82.5M	−$6.58M (−7.4%)

New holders (15)

Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to LCTX in Q4 2023
Institution	Shares	Value	% of portfolio
Susquehanna International Group, LLP	61,079	$66.6K	0.00%
Millennium Management LLC	57,998	$63.2K	0.00%
HRT Financial LP	35,923	$39.0K	0.00%
Cetera Advisor Networks LLC	30,628	$33.4K	0.00%
XTX Topco Ltd	27,037	$29.5K	0.01%
Farrow Financial Inc.	17,000	$18.5K	0.01%
Beacon Capital Management, LLC	15,000	$17.7K	0.00%
Madrona Financial Services, LLC	15,000	$16.4K	0.01%
Two Sigma Securities, LLC	12,704	$13.8K	0.00%
Fisher Asset Management, LLC	10,000	$10.9K	0.00%
The PNC Financial Services Group, Inc.	180	$196	0.00%
Planning Capital Management Corp	100	$109	0.00%
Strategic Investment Solutions, Inc.	44	$48	0.00%
Northwestern Mutual Wealth Management Co	20	$22	0.00%
Plante Moran Financial Advisors, LLC	2	$2	0.00%

Sold out (4)

Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of LCTX in Q4 2023
Institution	Shares, Q3 2023	Value, Q3 2023
D. E. Shaw & Co., Inc.	51,220	$60.4K
Summit X, LLC	10,925	$12.9K
USAdvisors Wealth Management, LLC	10,869	$12.0K
Metropolitan Life Insurance Co	7,125	$8.41K